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Abstract Clinical and psychosocial factors associated
separately with primary and secondary fatigue in Parkin-
son’s disease (PD) patients have not been thoroughly studied
before. The aim of our study was to assess factors associated
with different fatigue domains in groups with primary and
secondary fatigue in PD separately. We divided 165 non-
demented PD patients according to the absence/presence of
depression, anxiety and excessive somnolence into groups
with primary fatigue (N = 63) and with secondary fatigue
(N = 102). Fatigue domains examined using the multidi-
mensional fatigue inventory were associated through mul-
tiple linear regression analyses for each group separately
with sociodemographic data, disease duration, functional
status as assessed by the Unified Parkinson’s Disease Rating
Scale, treatment, depression, anxiety, excessive somnolence
and sleep quality. Out of the assessed non-motor symptoms,
fatigue was the most frequent (77.6 %). The prevalence of
fatigue in the secondary fatigue group was significantly
higher than in the primary fatigue group. Both fatigue groups
differed significantly in factors associated with different
fatigue domains. Functional status or other disease-related
factors were not associated with primary fatigue. In the
secondary fatigue group, we found associations between
some fatigue domains and functional status, older age, male
gender and higher anxiety scores. To our knowledge, this is
the first study to separately describe clinical determinants
and psychosocial factors associated with different fatigue
domains in primary and secondary fatigue in PD, underlin-
ing the importance of distinguishing primary and secondary
fatigue in future PD studies and clinical practice.
Keywords Parkinson’s disease  Primary fatigue 
Secondary fatigue  Depression  Anxiety 
Excessive daytime somnolence
Introduction
Fatigue is one of the most common non-motor symptoms
associated with Parkinson’s disease (PD), with a preva-
lence of up to 70 % among PD patients [1]. Fatigue was
found to be the most frequent of all non-motor symptoms
assessed in 1,072 consecutive patients examined in the
PRIAMO study [2]. Fatigue also has a significant impact
on quality of life [3, 4]. In one of the first studies on fatigue
in PD, 15–33 % of patients rated it as their most disabling
symptom, and more than half rated fatigue among their
three worst symptoms [5]. In a recent study of veterans
with PD, patients rated fatigue and pain as having the
greatest impact on their daily activities [6]. In a study
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which examined treatment expectations of PD patients,
fatigue was found to be the third most relevant problem [7].
The first articles highlighting the importance of fatigue in
PD were published only in 1993 [5, 8]; however, fatigue
has received more recognition only in the last decade.
Despite its high prevalence and importance, fatigue in PD
remains an under-recognized problem in routine clinical
practice [9].
There is currently no universally accepted definition of
fatigue. PD patients complaining about fatigue describe it
as being different from the fatigue they experienced before
developing PD [10]. Fatigue in PD can be divided into
‘‘peripheral fatigue’’, which refers to an objectively mea-
surable process in which a muscle loses strength after
repeated contractions, and ‘‘central fatigue’’, which refers
to a feeling-state, a perception or experience that is yet not
objectively measurable [1]. Central fatigue, which is the
main focus of this article, can be further divided into
physical and mental fatigue.
While more is known about the epidemiology and
importance of fatigue in PD, little is known about its
etiology, pathogenesis and possible management. One
reason is the probable heterogeneity of biological, clinical
and psychosocial factors leading to the presence of fati-
gue. In previous studies, disease severity, as measured by
the Unified Parkinson’s Disease Rating Scale (UPDRS),
was associated with fatigue only in some studies [11, 12],
while others found no such association [13, 14]. A sig-
nificant association between disease duration and fatigue
has not yet been proven. Indeed, fatigue is present in all
PD stages and was previously found in one-third of newly
diagnosed untreated, non-demented and non-depressed PD
patients [15]. Most previously published articles found a
strong link between fatigue and the presence of mood
disorders, especially depression [11, 13, 14] and excessive
daytime sleepiness (EDS) [16, 17]. Here is some overlap,
since fatigue is one of the DSM-IV diagnostic criteria for
depression and anxiety, making interpretation of fatigue
in the presence of such problems a major challenge. A
concept of primary and secondary fatigue has been pro-
posed, in which fatigue in the presence of mood disorders
or EDS is qualified as ‘secondary fatigue’ and fatigue
present in the absence of mood disorders and EDS is
addressed as ‘primary fatigue’ [18]. This concept was
later adopted in some other studies on fatigue in PD [19,
20]. To the best of our knowledge, studies on fatigue
published so far have been either epidemiological or have
studied clinical determinants associated with fatigue in
non-separated PD populations. Thus, the aim of our study
was to identify some clinical and psychosocial factors
associated with different fatigue domains separately in




Patients were recruited from 25 neurology outpatient
clinics in Eastern Slovakia between June 2011 and August
2012. All patients were diagnosed according to the United
Kingdom PD Society Brain Bank Clinical Criteria [21],
and their mental abilities were assessed with the Mini–
Mental State Examination (MMSE) [22]. A total of 205
patients initially agreed to participate in the study. Patients
with MMSE scores lower than 24 (N = 18), forms of
Parkinsonism other than idiopathic Parkinson’s disease,
(N = 8) and those who initially agreed to participate and
filled in the questionnaire but did not come for the oral
interview (N = 14) were excluded. A total of 165 non-
demented patients (80.5 %) remained for analysis.
Data collection
An invitation letter, written informed consent, and ques-
tionnaires comprising questions on sociodemographic
background, medical history, current medication and self-
report questionnaires (described below) were sent one
week before the interview by postal mail to patients diag-
nosed with PD. All self-report questionnaires used in our
study have good internal consistency, with Cronbach’s
alpha coefficients over 0.8. They have been previously
used in PD populations, and recommendations for their use
in PD have been published by the Movement Disorder
Society [23–26]. After one week, all patients were inter-
viewed by a trained interviewer on relevant issues that
were not part of the questionnaire, and their cognitive
functioning was assessed using the MMSE [22]. After this
structured interview, a single neurologist specialized in
Movement Disorders assessed each patient’s disease
severity using the UPDRS [27], including Hoehn and Yahr
staging [28]. Information on PD subtype (tremor dominant
versus akinetic-rigid) and the presence of postural insta-
bility ([2 steps on pull test) were recorded. Patients unable
to fill in the questionnaires themselves due to motor
impairment answered the questions during the oral inter-
view. The study was approved by the Local Ethics Com-
mittee. All patients participated voluntarily and provided
written informed consent prior to the interview.
Measures
Sociodemographic data, disease duration and medication
Demographic data including age, gender and education
were obtained from the structured interview. Education
level was classified as: low (apprenticeship or primary
J Neurol (2013) 260:1554–1561 1555
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school only), middle (finished secondary school) or high
(university). Information on disease duration, antiparkin-
sonian medication, and other treatment was also obtained
during the interview. The levodopa equivalent daily dosage
(LEDD) was counted using the formula published by
Tomlinson et al. [29].
Disease severity
Motor symptoms were rated in ON state by the UPDRS
part III. The UPDRS is a four-subscale combined scale
(mental state, activities of daily living, motor examination,
and complications) [27]. Scores were obtained via a semi-
structured interview and physical examination. The disease
stage was assessed using the Hoehn and Yahr scale (HY),
which is applied to gauge the course of the disease over
time [28].
Anxiety and depression
The Beck depression inventory-II (BDI-II) is a self-
administered, 21-item scale assessing depression [30].
Each answer was scored as 0–3. Cutoff values used are
0–13: normal range; 14–19: mild depression; 20–28:
moderate depression; and 29–63: severe depression [30].
Higher total scores indicate more severe depressive
symptoms.
The Hospital Anxiety and Depression Scale (HADS) is a
self-administered scale with two subscales capable of
evaluating anxiety (HADS-A) and depression (HADS-D)
[31]. This 14-item scale consists of seven items assessing
anxiety and seven items assessing depression, with scoring
from 0 (no problem) to 3 (extreme problem). Cut-off values
applied are: B7 on each subscale is considered unimpaired;
8–10 on each subscale: possibly impaired; and C11 on each
subscale: probably impaired [31].
Sleep measures
Excessive daytime somnolence (EDS) was evaluated with
the Epworth Sleepiness Scale (ESS) [32]. ESS measures
dozing behavior in eight different situations. This self-
assessment questionnaire asks the respondent to rate the
likelihood of falling asleep on a scale from 0 to 3. The total
ESS score is the sum of all the responses and ranges from 0
to 24; higher scores reflect greater sleep propensity. Con-
sistent with a number of previous investigations, a score of
10 as the cut-off point was used for normal, while scores
above this imply pathological sleepiness [26].
The Pittsburgh Sleep Quality Index (PSQI) [33] was
used to assess nighttime sleeping problems. The PSQI
assesses global sleep quality and disturbances in sleep
patterns during the previous month in seven components.
After recoding, each component has possible scores of 0–3,
where 3 indicates the negative extreme. The global PSQI
score is the sum of all component scores (range 0–21); a
score of C5 indicates a poor sleeper.
Fatigue
Fatigue was assessed with the 20-item self-report multidi-
mensional fatigue inventory (MFI) [34], which measures
five dimensions of fatigue: general fatigue, physical fati-
gue, reduced activity, reduced motivation, and mental
fatigue. Each subscale contains four items, which are
scored on a five-point Likert-scale. The negative formu-
lated items must be recoded before totaling the scores.
Scores range from 4 (absence of fatigue) to 20 (maximum
fatigue) for each subscale. Its reliability and structural
validity in patients with idiopathic PD has been recently
published [35]. We used a uniform cutoff score of C13 in
each MFI domain to define the presence of fatigue. This
was in accordance with a previously published MFI general
fatigue domain cutoff score of C13 for defining severe
fatigue in chronic fatigue syndrome [36].
Statistical analysis
Statistical analyses were performed using the PASW SPSS
version 18.0 statistical software for Windows (SPSS Inc,
Chicago, IL, USA). Patients were divided into two groups.
The group with ‘‘primary fatigue’’ was characterized by the
absence of depression (BDI-II B 13), anxiety (HADS-
A \ 11) and EDS (ESS B 10). The group with ‘‘secondary
fatigue’’ was characterized by the presence of depression
(BDI [ 13), anxiety (HADS-A C 11) or EDS (ESS [ 10).
First, we described the demographic and clinical charac-
teristics of our studied groups. Significant differences
between the group characteristics were counted by inde-
pendent sample t tests and chi-square tests. Then, the
relationships between age, gender, education level, disease
duration, functional status, LEDD, depression, anxiety,
EDS and sleep quality were analyzed with multiple linear
regression analysis, using all separate fatigue domains as
dependent variables in both groups of patients separately.
Results
The average age of the total PD sample was 69.7 ±
8.5 years; average disease duration was 6.9 ± 4.8 (range
0–30 years), and the average Hoehn and Yahr stage was
2.4 ± 0.9. A total of 128 patients (77.6 % of the whole
sample) were fatigued in at least one MFI domain. After
dividing the sample, 102 patients remained in the group
with a mood disorder or EDS present (‘‘secondary fatigue’’
1556 J Neurol (2013) 260:1554–1561
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group) and 63 remained in the group with no mood dis-
order and EDS (‘‘primary fatigue’’ group). The two fatigue
groups did not differ significantly in age, gender distribu-
tion, education level, PD subtype or treatment. The sec-
ondary fatigue group had longer disease duration (7.5 vs.
6 years), a higher HY stage (2.6 vs. 2.1), higher scores in
all UPDRS subscales, higher fatigue scores, and a higher
prevalence of fatigue in all MFI domains. Fatigue associ-
ated with physical aspects was more frequent than fatigue
associated with mental aspects in both groups. Baseline
characteristics of the study groups can be found in Table 1.
Determinants of fatigue in the secondary fatigue group
Older age was strongly associated with higher reduced
motivation and mental fatigue scores. Male gender was
related to higher reduced activity and mental fatigue.
UPDRS-III was significantly associated with more fatigue
in all domains except mental fatigue, and anxiety was
associated with reduced motivation. Depression and sleep
problems were not associated with any MFI domain in this
group.
Determinants of fatigue in the primary fatigue group
The only variable significantly associated with MFI
reduced activity and mental fatigue domains was BDI-II,
even though in the normality range. A similar relation was
also found between HADS-D and fatigue in the normality
range when the sample was divided according to HADS-D
(B10 pts) instead of BDI (results not shown). UPDRS-III
was not associated with any of the MFI domains in this
group. There were no determinants related to general
fatigue, physical fatigue and reduced motivation in the
primary fatigue group Table 2.
Discussion
To the best of our knowledge, this is the first study to
separately describe clinical determinants and psychosocial
factors associated with different fatigue domains in pri-
mary and secondary fatigue in Parkinson’s disease. Out of
the measured non-motor symptoms, fatigue present in at
least one of the MFI domains was the most frequent non-
motor symptom, found in 77.6 % of our study population.
We found the prevalence of fatigue to be higher than is
described in previous studies [15–17], which mostly used
uni-dimensional fatigue rating scales. MFI scores and the
prevalence of fatigue are significantly higher in the phys-
ical domains of fatigue in both groups than in the mental
domains, which could be explained by the stronger impact
of core motor features of PD on the physical abilities of
patients [11]. Both primary and secondary fatigue differed
significantly in baseline characteristics and factors associ-
ated with different fatigue domains.
Older age was found to be significantly associated with
reduced motivation and mental fatigue in the secondary
fatigue group, but not in the primary. Fatigue is a common
problem in older adults and has been suggested as being a
part of the normal aging process [37]. The higher preva-
lence of fatigue in PD, however, cannot be explained only
by older age. In contrast with our finding, most previous
studies found no association between older age and fatigue
in PD [11, 17]. A recent study on fatigue in early PD found
a significant correlation between higher fatigue scores and
older age, but when linear regression analysis was applied,
only depression and UPDRS activities of daily living
subscale remained significant in their population [38]. In
contrast with some previous studies, where higher preva-
lence of fatigue was found in women [39], we found a
significant association of MFI domains mental fatigue and
reduced motivation with male gender, but only in the
secondary fatigue group.
In line with previous findings, disease duration was not
related to any of the fatigue domains [11, 17]. There were
no differences in antiparkinsonian medication between the
primary and secondary fatigue groups. Although some
previous studies have suggested a potential effect of
dopaminergic treatment on at least some aspects of fatigue
[15, 40–42], we did not find any association between
LEDD and any of the fatigue domains in either primary or
secondary fatigue.
Functional status, measured by UPDRS-III, was signif-
icantly worse in the secondary fatigue group compared
with the primary. It was also significantly associated with
all fatigue domains except mental fatigue in the secondary
fatigue group, but not in the primary fatigue group. Pre-
vious studies have found conflicting results regarding the
association of functional status with fatigue in PD [11–14].
One reason for this incongruity may lie in the selection of
different patient samples.
Depressive symptoms and excessive somnolence are
significantly associated with more fatigue in PD [1, 11, 14],
and the prevalence of fatigue is significantly higher in this
population of patients, as found in our study. One impor-
tant finding is that with patients in the secondary fatigue
group, the severity of depression or sleepiness did not play
a further role in explaining any of the fatigue domains in
that group. Higher anxiety scores contributed to the
explanation of reduced motivation in the secondary fatigue
group.
Of interest is the fact that BDI-II, even though in the
normal range, is the only factor associated with reduced
activity and mental fatigue in the primary fatigue group.
When we divided the study sample according to HADS-D,
J Neurol (2013) 260:1554–1561 1557
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Table 1 Baseline
characteristics of the study
population (N = 165)
UDPRS unified Parkinson’s
disease rating scale, BDI-II Beck
depression inventory-II, HADS
hospital anxiety and depression
scale, ESS Epsworth sleepiness
scale, PSQI Pittsburgh sleep
quality index, MFI
multidimensional fatigue
inventory, LEDD total levodopa
equivalent daily dosage, ns non-
significant
Bold values indicate the






primary and secondary fatigue groups
Number of patients 102 63
Gender (male/female) 51/51 35/28 p = ns
Age 70.2 ± 8.4 68.6 ± 8.8 p = ns
Disease duration 7.5 ± 5.3 6.0 ± 3.7 p = 0.04
Education level
Low 40 (39 %) 29 (46 %) p = ns
Middle 42 (41 %) 23 (37 %)
High 20 (20 %) 11 (17 %)
Hoehn and Yahr stage 2.6 ± 0.9 2.1 ± 0.8 p = 0.002
H&Y B 2 44 (43 %) 46 (73 %)
H&Y [ 2 58 (57 %) 17 (27 %)
UPDRS_I 2.0 ± 2.1 0.6 ± 1.1 p < 0.001
UPDRS_II 14.9 ± 7.7 8.1 ± 5.5 p < 0.001
UPDRS_III 33.2 ± 13.7 25.1 ± 12.0 p < 0.001
Motor fluctuations 58 (57 %) 26 (41 %) p < 0.05
PD subtype
Tremor dominant 21 (20 %) 17 (27 %) p = ns
Akinetic-rigid 82 (80 %) 46 (73 %)
Postural instability
([2 steps on pull test)
65 (63 %) 21 (33 %) p < 0.001
BDI 21.2 ± 9.0 8.4 ± 3.5 p < 0.001
[13 pts 94 (91 %) 0
HADS depression 8.0 ± 3.4 3.9 ± 2.5 p < 0.001
C11 pts 26 (26 %) 0
HADS anxiety 8.2 ± 4.0 4.1 ± 2.9 p < 0.001
C11 pts 28 (28 %) 0
ESS 8.4 ± 4.7 5.1 ± 2.6 p < 0.001
[10 pts 38 (37 %) 0
PSQI 8.9 ± 4.1 6.0 ± 3.4 p < 0.001
C5 pts 86 (84 %) 40 (64 %)
MFI general fatigue 15.2 ± 3.0 11.4 ± 3.6
C13 pts 83 (81 %) 20 (32 %) p < 0.001
MFI physical fatigue 15.0 ± 3.4 11.6 ± 3.6
C13 pts 77 (75 %) 25 (40 %) p < 0.001
MFI reduced activity 13.4 ± 3.5 10.6 ± 4.1
C13 57 (55 %) 18 (29 %) p < 0.001
MFI reduced motivation 10.7 ± 3.4 8.3 ± 3.1
C13 30 (29 %) 7 (11 %) p < 0.001
MFI mental fatigue 11.7 ± 3.6 8.6 ± 3.0
C13 37 (36 %) 4 (7 %) p < 0.001
LEDD (mg/day) 569 (0–2972) 468 (0–1,525) p = ns
L-Dopa 71 (69 %) 40 (63 %) p = ns
L-Dopa ? COMT inhibitor 41 (40 %) 19 (30 %) p = ns
Dopamine agonist 65 (63 %) 45 (71 %) p = ns
L-Dopa ? dopamine agonist 43 (42 %) 27 (43 %) p = ns
No dopaminergic treatment 10 (10 %) 6 (9 %) p = ns
Rasagiline 37 (36 %) 21 (33 %) p = ns
Amantadine 23 (22 %) 11 (18 %) p = ns
1558 J Neurol (2013) 260:1554–1561
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a correlation of fatigue with increased scores of HADS-D
in the normal range were also found. A study of fatigue in
levodopa-naı¨ve PD patients published by Schiffito et al.
[15] found a similar correlation of fatigue with Hamilton
Depression Scale scores in the normal range. Primary
fatigue in our study was unrelated to functional status,
LEDD or other disease-related factors, pointing to a
potentially different mechanism underlying fatigue in this
group of patients. This is supported by the results of a
previously published ELLDOPA trial, where the [123I]-b-
CIT SPECT striatal dopamine transporter density was not
related to fatigue [15]. On the other hand, a PET study in
primary fatigue published by Pavese et al. [20] found an
association between fatigue and a relative serotonergic
denervation in the basal ganglia and associated limbic
circuits and F-dopa uptake reduction in the insular region,
but not in basal ganglia, thus suggesting a serotonin-related
basis for fatigue in PD. Although selective serotonin
reuptake inhibitors (SSRI) are commonly used in the
treatment of chronic fatigue, clinical experience reveals
that they are not very useful in treating fatigue in PD [1].
Pavese et al. [20] further discuss that due to an effective
loss of SERT protein found in their study, SSRI are less
likely to be efficacious in PD patients with primary fatigue.
A previous observational study by Martinez-Martin et al.
[43] found a lower prevalence of fatigue in patients treated
with amantadine, which is often used to treat fatigue in
multiple sclerosis as well. In our study we did not find an
association between amantadine intake and any of the
fatigue domains in either the primary or secondary fatigue
groups. The only report of successful treatment of fatigue
in PD thus far is a double-blind randomized placebo-con-
trolled trial of 36 non-depressed PD patients with methyl-
phenidate 10 mg t.i.d. [44]. This study is also noted in the
report of Quality Standards Subcommittee of the American
Academy of Neurology on the treatment of non-motor
symptoms of PD as the only publication showing
improvement of fatigue in PD (evidence level C) [45].
However, due to the stimulant effects of methylphenidate,
its use, especially in elderly PD patients with cardiovas-
cular problems, is relatively contraindicated.
Strengths and limitations
To the best of our knowledge, this is the first study which
evaluated clinical determinants of primary and secondary
fatigue domains in PD patients separately. Using a multi-
dimensional fatigue scale with good psychometric qualities
in PD patients enabled us to better explore associations of
studied variables with different aspects of fatigue in PD.
There were some limitations in this study, however. The
concept of primary and secondary fatigue in PD needs
further validation. Another limitation of our study is that
anxiety, depression and excessive somnolence were eval-
uated by means of self-report questionnaires only. Our
study sample consisted of more motivated patients who
agreed to participate in the study and who were able to
Table 2 Determinants associated with the MFI fatigue domains in the divided PD sample
MFI
Secondary fatigue group Primary fatigue group
GenF PhyF RedA RedM MentF GenF PhyF RedA RedM MentF
Age 0.14 0.15 0.16 0.34*** 0.29** -0.25 -0.18 -0.03 0.11 -0.01
Male gender 0.00 0.00 0.25* 0.09 0.22* -0.05 -0.21 -0.02 0.08 -0.01
Higher education level -0.04 -0.09 -0.11 -0.13 -0.16 0.02 -0.01 0.02 -0.18 -0.10
Disease duration -0.20 0.05 0.08 -0.05 0.04 -0.00 0.10 0.15 0.00 -0.03
UPDRS III 0.28* 0.25* 0.28** 0.19* 0.05 0.20 0.13 0.12 0.03 -0.03
LEDD (mg/day) 0.04 0.06 0.09 -0.17 -0.10 -0.20 -0.03 -0.07 -0.02 -0.13
ESS 0.12 0.04 0.09 0.03 0.07 0.22 0.11 -0.23 -0.18 -0.05
PSQI 0.20 0.08 0.08 0.15 0.10 0.13 0.14 0.10 0.12 0.22
BDI 0.04 -0.01 0.08 0.13 0.19 0.07 0.09 0.32* 0.12 0.39*
HADS-A 0.00 0.04 -0.00 0.22* 0.20 0.23 -0.00 0.03 -0.06 -0.07
R square 0.21 0.13 0.24 0.39 0.29 0.29 0.17 0.20 0.09 0.25
Adj. R square 0.12 0.03 0.15 0.32 0.21 0.15 0.02 0.05 -0.09 0.10
MFI multidimensional fatigue inventory, GenF general fatigue, PhyF physical fatigue, RedA reduced activity, RedM reduced motivation, MentF
mental fatigue, UDPRS III unified Parkinson’s disease rating scale, LEDD total L-dopa equivalent daily dosage, ESS Epsworth sleepiness scale,
PSQI Pittsburgh sleep quality index, BDI-II Beck depression inventory-II, HADS-A hospital anxiety and depression scale-anxiety subscale
* p \ 0.05, ** p \ 0.01, *** p \ 0.001
J Neurol (2013) 260:1554–1561 1559
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attend the examination. Also, the cross-sectional design of
the study does not allow us to further explore the causal
pathways between the studied variables.
Implications for future studies and clinical practice
As found in our study, primary and secondary fatigue consist
of distinct samples of PD patients and are determined by
different clinical and psychosocial factors. Future studies
investigating fatigue should therefore be conducted separately
in primary and secondary fatigue groups. Primary fatigue in
our study sample did not correlate with disease severity or
other disease-related factors in any of the domains, indicating
a possibly different underlying mechanism.
In clinical practice, fatigue is one of the most common
non-motor symptoms of PD leading to a decreased quality
of life. In the secondary fatigue group, efforts should be
taken to optimally treat motor symptoms of the disease and
to identify and properly manage depression, anxiety and
EDS associated with PD, since at least some patients with
secondary fatigue might benefit from these measures. So
far little is known about the pathophysiology underlying
primary fatigue in PD, and although some evidence exists
for using methylphenidate in the treatment of primary
fatigue in PD, due to its stimulant effects it is useful only in
PD patients without cardiovascular problems. Further
research on the etiology and pathophysiology of primary
fatigue in PD should be encouraged to reveal its underlying
mechanism and enable management of this condition.
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